SAG yields 198.02% · JNJ yields 2.13%● Live data
📍 SAG pulled ahead of the other in Year 1
Combined, SAG + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SAG + JNJ for your $10,000?
SAG Holdings Limited, through its subsidiaries, distributes and sells automotive and industrial spare parts in the Asia Pacific, the Middle East, Europe, Africa, and the Americas. It operates in two segments, On-Highway Business and Off-Highway Business. The On-Highway Business segment supplies genuine original equipment manufacturer (OEM) and aftermarket parts, engine and chassis parts, wear and tear parts, body parts, and spare parts and lubricants for use in passenger and commercial vehicles. This segment serves resellers, such as distributors and dealers of automotive parts, retailers, workshops, end-users, and fleet owners. The Off-Highway Business segment supplies a range of filters, batteries, lubricants, components, and industrial spare parts for internal combustion engines for various sectors, including marine, energy, mining, construction, agriculture, and oil and gas. This segment serves distributors and dealers of industrial parts that are resold to workshops, industrial manufacturing facilities, shipyards, and heavy-duty transport fleet owners. The company also manufactures and distributes automotive spare parts and lubricants under the REV-1, VETTO, NUTEQ, GENTEQ, and SUNBLADE brands. In addition, it offers its products through retail outlets. The company was incorporated in 2022 and is based in Singapore. SAG Holdings Limited is a subsidiary of Soon Aik Global Pte Ltd.
Full SAG Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.